• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基因稳定的黏液样/圆形细胞脂肪肉瘤中的正常且具有功能的TP53

Normal and functional TP53 in genetically stable myxoid/round cell liposarcoma.

作者信息

Ståhlberg Anders, Kåbjörn Gustafsson Christina, Engtröm Katarina, Thomsen Christer, Dolatabadi Soheila, Jonasson Emma, Li Chieh-Yuan, Ruff David, Chen Shiaw-Min, Åman Pierre

机构信息

Sahlgrenska Cancer Center, Department of Pathology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.

Department of Oncology, Institute of Medical Sciences, University of Gothenburg, Gothenburg, Sweden.

出版信息

PLoS One. 2014 Nov 13;9(11):e113110. doi: 10.1371/journal.pone.0113110. eCollection 2014.

DOI:10.1371/journal.pone.0113110
PMID:25393000
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4231113/
Abstract

Myxoid/round-cell liposarcoma (MLS/RCLS) is characterized by either the fusion gene FUS-DDIT3 or the less commonly occurring EWSR1-DDIT3 and most cases carry few or no additional cytogenetic changes. There are conflicting reports concerning the status and role of TP53 in MLS/RCLS. Here we analysed four MLS/RCLS derived cell lines for TP53 mutations, expression and function. Three SV40 transformed cell lines expressed normal TP53 proteins. Irradiation caused normal posttranslational modifications of TP53 and induced P21 expression in two of these cell lines. Transfection experiments showed that the FUS-DDIT3 fusion protein had no effects on irradiation induced TP53 responses. Ion Torrent AmpliSeq screening, using the Cancer Hotspot panel, showed no dysfunctional or disease associated alleles/mutations. In conclusion, our results suggest that most MLS/RCLS cases carry functional TP53 genes and this is consistent with the low numbers of secondary mutations observed in this tumor entity.

摘要

黏液样/圆细胞脂肪肉瘤(MLS/RCLS)的特征是具有融合基因FUS-DDIT3或较少见的EWSR1-DDIT3,并且大多数病例几乎没有或没有其他细胞遗传学改变。关于TP53在MLS/RCLS中的状态和作用存在相互矛盾的报道。在此,我们分析了四种源自MLS/RCLS的细胞系的TP53突变、表达和功能。三种SV40转化的细胞系表达正常的TP53蛋白。辐射导致TP53正常的翻译后修饰,并在其中两种细胞系中诱导P21表达。转染实验表明,FUS-DDIT3融合蛋白对辐射诱导的TP53反应没有影响。使用癌症热点面板进行的Ion Torrent AmpliSeq筛查未发现功能失调或与疾病相关的等位基因/突变。总之,我们的结果表明,大多数MLS/RCLS病例携带功能性TP53基因,这与在该肿瘤实体中观察到的继发性突变数量较少一致。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/002b/4231113/5912dce4cfaa/pone.0113110.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/002b/4231113/4fa61d1f7ae9/pone.0113110.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/002b/4231113/5912dce4cfaa/pone.0113110.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/002b/4231113/4fa61d1f7ae9/pone.0113110.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/002b/4231113/5912dce4cfaa/pone.0113110.g002.jpg

相似文献

1
Normal and functional TP53 in genetically stable myxoid/round cell liposarcoma.基因稳定的黏液样/圆形细胞脂肪肉瘤中的正常且具有功能的TP53
PLoS One. 2014 Nov 13;9(11):e113110. doi: 10.1371/journal.pone.0113110. eCollection 2014.
2
Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop.FUS-DDIT3 型黏液样脂肪肉瘤中 FLT1 的核表达及其配体 PGF 提示存在一个内源性信号环路。
BMC Cancer. 2010 Jun 1;10:249. doi: 10.1186/1471-2407-10-249.
3
The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells.黏液样/圆形细胞脂肪肉瘤融合致癌基因FUS-DDIT3和正常DDIT3在转染的人纤维肉瘤细胞中诱导脂肪肉瘤表型。
Am J Pathol. 2006 May;168(5):1642-53. doi: 10.2353/ajpath.2006.050872.
4
The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ.黏液样脂肪肉瘤FUS-DDIT3融合癌蛋白通过与NFKBIZ相互作用来失调NF-κB靶基因。
Oncogene. 2009 Jan 15;28(2):270-8. doi: 10.1038/onc.2008.378. Epub 2008 Oct 13.
5
Regulatory mechanisms, expression levels and proliferation effects of the FUS-DDIT3 fusion oncogene in liposarcoma.脂肪肉瘤中FUS-DDIT3融合癌基因的调控机制、表达水平及增殖效应
J Pathol. 2016 Apr;238(5):689-99. doi: 10.1002/path.4700.
6
HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo.热休克蛋白90(HSP90)抑制可阻断黏液样/圆形细胞脂肪肉瘤中ERBB3和RET的磷酸化,并在体外和体内导致大量细胞死亡。
Oncotarget. 2016 Jan 5;7(1):433-45. doi: 10.18632/oncotarget.6336.
7
Molecular aberrations of the G1-S checkpoint in myxoid and round cell liposarcoma.黏液样和圆形细胞脂肪肉瘤中G1-S期检查点的分子异常
Am J Pathol. 1997 Dec;151(6):1531-9.
8
Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis.黏液样/圆细胞脂肪肉瘤圆形细胞成分中p16(INK4a)/p14(ARF)和p53通路的频繁改变:p53基因改变和p14(ARF)表达降低均与预后不良相关。
J Pathol. 2005 Dec;207(4):410-21. doi: 10.1002/path.1848.
9
DDIT3/CHOP and the sarcoma fusion oncoprotein FUS-DDIT3/TLS-CHOP bind cyclin-dependent kinase 2.DNA损伤诱导转录因子3/CCAAT增强子结合蛋白同源蛋白(DDIT3/CHOP)和肉瘤融合致癌蛋白FUS-DDIT3/ TLS-CHOP与细胞周期蛋白依赖性激酶2结合。
BMC Cell Biol. 2009 Dec 17;10:89. doi: 10.1186/1471-2121-10-89.
10
Deciphering the role of FUS::DDIT3 expression and tumor microenvironment in myxoid liposarcoma development.解析FUS::DDIT3表达和肿瘤微环境在黏液样脂肪肉瘤发生发展中的作用。
J Transl Med. 2024 Apr 26;22(1):389. doi: 10.1186/s12967-024-05211-w.

引用本文的文献

1
Intratumoral heterogeneity of cancer driver genomic alterations in myxoid liposarcomas.黏液样脂肪肉瘤中癌症驱动基因改变的肿瘤内异质性
Cancer. 2025 Jun 15;131(12):e35937. doi: 10.1002/cncr.35937.
2
Deciphering the role of FUS::DDIT3 expression and tumor microenvironment in myxoid liposarcoma development.解析FUS::DDIT3表达和肿瘤微环境在黏液样脂肪肉瘤发生发展中的作用。
J Transl Med. 2024 Apr 26;22(1):389. doi: 10.1186/s12967-024-05211-w.
3
Digital RNA sequencing using unique molecular identifiers enables ultrasensitive RNA mutation analysis.

本文引用的文献

1
Mode of action of trabectedin in myxoid liposarcomas. trabectedin 在黏液样脂肪肉瘤中的作用机制。
Oncogene. 2014 Oct 30;33(44):5201-10. doi: 10.1038/onc.2013.462. Epub 2013 Nov 11.
2
A conserved N-terminal motif is required for complex formation between FUS, EWSR1, TAF15 and their oncogenic fusion proteins.一个保守的 N 端基序对于 FUS、EWSR1、TAF15 及其致癌融合蛋白之间的复合物形成是必需的。
FASEB J. 2013 Dec;27(12):4965-74. doi: 10.1096/fj.13-234435. Epub 2013 Aug 23.
3
Surf the post-translational modification network of p53 regulation.
采用独特分子标识符的数字 RNA 测序可实现超灵敏的 RNA 突变分析。
Commun Biol. 2024 Mar 1;7(1):249. doi: 10.1038/s42003-024-05955-7.
4
The Conundrum of Dedifferentiation in a Liposarcoma at a Peculiar Location: A Case Report and Literature Review.位置特殊的去分化脂肪肉瘤的难题:病例报告及文献复习。
Medicina (Kaunas). 2023 May 17;59(5):967. doi: 10.3390/medicina59050967.
5
Myxoid Liposarcomas: Systemic Treatment Options.黏液样脂肪肉瘤:全身治疗选择
Curr Treat Options Oncol. 2023 Apr;24(4):274-291. doi: 10.1007/s11864-023-01057-4. Epub 2023 Feb 28.
6
DIscBIO: A User-Friendly Pipeline for Biomarker Discovery in Single-Cell Transcriptomics.DIscBIO:单细胞转录组学中生物标志物发现的用户友好型流程。
Int J Mol Sci. 2021 Jan 30;22(3):1399. doi: 10.3390/ijms22031399.
7
Total mRNA Quantification in Single Cells: Sarcoma Cell Heterogeneity.单细胞中总 mRNA 的定量:肉瘤细胞异质性。
Cells. 2020 Mar 19;9(3):759. doi: 10.3390/cells9030759.
8
Liposarcoma: Advances in Cellular and Molecular Genetics Alterations and Corresponding Clinical Treatment.脂肪肉瘤:细胞与分子遗传学改变及相应临床治疗的进展
J Cancer. 2020 Jan 1;11(1):100-107. doi: 10.7150/jca.36380. eCollection 2020.
9
IGF2/IGF1R Signaling as a Therapeutic Target in MYB-Positive Adenoid Cystic Carcinomas and Other Fusion Gene-Driven Tumors.IGF2/IGF1R 信号作为 MYB 阳性腺样囊性癌和其他融合基因驱动肿瘤的治疗靶点。
Cells. 2019 Aug 16;8(8):913. doi: 10.3390/cells8080913.
10
FET family fusion oncoproteins target the SWI/SNF chromatin remodeling complex.FET 家族融合癌蛋白靶向 SWI/SNF 染色质重塑复合物。
EMBO Rep. 2019 May;20(5). doi: 10.15252/embr.201845766. Epub 2019 Apr 8.
探索 p53 调控的翻译后修饰网络。
Int J Biol Sci. 2012;8(5):672-84. doi: 10.7150/ijbs.4283. Epub 2012 May 10.
4
FUS-CHOP fusion protein expression coupled to p53 deficiency induces liposarcoma in mouse but not in human adipose-derived mesenchymal stem/stromal cells.FUS-CHOP 融合蛋白表达与 p53 缺失导致脂肪肉瘤在小鼠中发生,但不在人脂肪来源的间充质干细胞/基质细胞中发生。
Stem Cells. 2011 Feb;29(2):179-92. doi: 10.1002/stem.571.
5
Nonrandom secondary chromosome-aberrations in liposarcomas with t(12, 16).伴有t(12, 16)的脂肪肉瘤中的非随机继发性染色体畸变。
Int J Oncol. 1994 Feb;4(2):307-10. doi: 10.3892/ijo.4.2.307.
6
Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors.模拟人类肿瘤生物学和药理学特征的黏液样脂肪肉瘤异种移植新型模型。
Clin Cancer Res. 2010 Oct 15;16(20):4958-67. doi: 10.1158/1078-0432.CCR-10-0317. Epub 2010 Aug 20.
7
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.亚型特异性基因组改变为软组织肉瘤治疗确定新的靶点。
Nat Genet. 2010 Aug;42(8):715-21. doi: 10.1038/ng.619. Epub 2010 Jul 4.
8
The isoforms of the p53 protein.p53 蛋白的异构体。
Cold Spring Harb Perspect Biol. 2010 Mar;2(3):a000927. doi: 10.1101/cshperspect.a000927.
9
Massively regulated genes: the example of TP53.大量调控的基因:以 TP53 为例。
J Pathol. 2010 Jan;220(2):164-73. doi: 10.1002/path.2637.
10
Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.曲贝替定(ET - 743)可促进黏液样脂肪肉瘤肿瘤的分化。
Mol Cancer Ther. 2009 Feb;8(2):449-57. doi: 10.1158/1535-7163.MCT-08-0848. Epub 2009 Feb 3.